Genetic Technologies Croissance future

Future contrôle des critères 0/6

Nous ne disposons actuellement pas d'une couverture d'analyste suffisante pour prévoir la croissance et les revenus de Genetic Technologies.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Life Sciences croissance des bénéfices	20.7%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Genetic Technologies Limited's (ASX:GTG) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 15

Should You Take Comfort From Insider Transactions At Genetic Technologies Limited (ASX:GTG)?

Dec 17

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme Genetic Technologies n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

ASX:GTG - Estimations futures des analystes et données financières antérieures (AUD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2024	10	-12	-10	-10	N/A
3/31/2024	10	-12	-9	-9	N/A
12/31/2023	10	-13	-8	-8	N/A
9/30/2023	10	-12	-9	-9	N/A
6/30/2023	10	-12	-10	-10	N/A
3/31/2023	11	-10	-9	-9	N/A
12/31/2022	11	-9	-8	-8	N/A
9/30/2022	10	-8	-7	-7	N/A
6/30/2022	9	-7	-6	-6	N/A
3/31/2022	7	-7	-6	-6	N/A
12/31/2021	5	-7	-7	-7	N/A
9/30/2021	3	-7	-7	-6	N/A
6/30/2021	1	-7	-7	-6	N/A
3/31/2021	2	-7	-7	-6	N/A
12/31/2020	0	-7	-7	-7	N/A
9/30/2020	0	-7	-6	-6	N/A
6/30/2020	1	-6	-6	-6	N/A
3/31/2020	0	-6	-6	-5	N/A
12/31/2019	0	-6	-5	-5	N/A
9/30/2019	0	-6	-6	-6	N/A
6/30/2019	0	-6	-6	-6	N/A
3/31/2019	0	-6	-6	-6	N/A
12/31/2018	0	-5	-6	-6	N/A
9/30/2018	0	-5	-6	-6	N/A
6/30/2018	0	-5	-6	-6	N/A
3/31/2018	0	-7	N/A	-6	N/A
12/31/2017	0	-8	N/A	-6	N/A
9/30/2017	0	-8	N/A	-7	N/A
6/30/2017	1	-8	N/A	-7	N/A
3/31/2017	1	-8	N/A	-7	N/A
12/31/2016	1	-8	N/A	-7	N/A
9/30/2016	1	-8	N/A	-7	N/A
6/30/2016	1	-8	N/A	-8	N/A
3/31/2016	1	-8	N/A	-8	N/A
12/31/2015	1	-8	N/A	-8	N/A
9/30/2015	2	-9	N/A	-9	N/A
6/30/2015	2	-9	N/A	-10	N/A
3/31/2015	3	-9	N/A	-11	N/A
12/31/2014	4	-10	N/A	-12	N/A
9/30/2014	4	-10	N/A	-11	N/A
6/30/2014	5	-10	N/A	-11	N/A
3/31/2014	4	-10	N/A	-10	N/A
12/31/2013	4	-11	N/A	-10	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de GTG est supérieure au taux d'épargne ( 2.6% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de GTG devraient croître plus rapidement que le marché Australian

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de GTG devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de GTG devraient croître plus rapidement que le marché Australian.

Croissance élevée des revenus: Données insuffisantes pour déterminer si les revenus de GTG devraient croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de GTG devrait être élevé dans 3 ans

Genetic Technologies Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Full year 2024 earnings released: AU$0.091 loss per share (vs AU$0.12 loss in FY 2023)

Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.12 loss in FY 2023)

Genetic Technologies Limited Announces Global Launch of GeneType on Wholly Owned EasyDNA Platform

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of AUD 1.71026 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of AUD 3.997793 million.

Genetic Technologies Limited Appoints Mark Ziirsen as Chief Financial Officer

Genetic Technologies Limited Announces Resignation of Kathryn Andrews as CFO

Genetic Technologies Limited Share the Power of the geneType Test in Identifying Risk and Improving the Health of Populations Worldwide

New major risk - Revenue and earnings growth

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $2 million.

New minor risk - Shareholder dilution

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $11.2056 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $2 million.

Genetic Technologies Limited Establishes Clinical Implementation Study with Breast Screen Centres Across New York, Miami and Houston

Genetic Technologies Limited to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

Independent Non-Executive Chairman recently bought AU$80k worth of stock

New major risk - Financial position

Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Market cap size

Genetic Technologies Limited's (ASX:GTG) CEO Will Probably Find It Hard To See A Huge Raise This Year

Genetic Technologies Limited, Annual General Meeting, Nov 22, 2023

Genetic Technologies Limited Announces the Expanded GeneType Multi-Risk Test Is Now Available to Order in Australia

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Genetic Technologies Limited Announces Publication Highlights Genetype’S Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

Genetic Technologies Limited Provides Further Update on Comprehensive Risk Test for Breast & Ovarian Cancer

Genetic Technologies Limited to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

Non-Independent Non-Executive Director recently sold AU$77k worth of stock

Genetic Technologies Limited Published in Plus One for Cvd & Type 2 Diabetes

Genetic Technologies Limited, Annual General Meeting, Nov 28, 2022

Genetic Technologies Limited Appoints Tony Di Pietro as Chief Financial Officer

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2021)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of eCommerce Business and Distribution Rights of AffinityDNA from Affinity DNA Limited.

Genetic Technologies Limited Announces Resignation of Michael Tonroe as Company Secretary

Genetic Technologies Limited Commences Initial Implementation of its geneType Risk Assessment Test at 16 Medical Practices Across the East Coast of Australia

Genetic Technologies Limited Announces the Completion of an Independently Developed and Validated Customisable Budget Impact Model

Genetic Technologies Limited (ASX:GTG) entered into an agreement to acquire eCommerce Business and Distribution Rights of AffinityDNA from Affinity Dna Limited for £0.555 million

Genetic Technologies Limited Announces GeneType Multi-Test Approves for Commercial Release

High number of new and inexperienced directors

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of General Genetics Corporation from BelHealth Investment Fund, L.P. managed by BelHealth Investment Partners, LLC.

Company Secretary Justyn Stedwell has left the company

Genetic Technologies Limited Confirms the Launch of GTG's Covid-19 Serious Disease Risk Test (`Covid-19 Risk Test') by US Based Infinity Biologix LLC

Genetic Technologies Limited Provides COVID-19 Risk Test Launch Update

Genetic Technologies Limited Signs 3-Year US Licence Agreement for COVID Risk Test

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $6.5625 million.

Genetic Technologies Limited Provides Update on Its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing

Genetic Technologies Limited Announces Management Changes

Should You Take Comfort From Insider Transactions At Genetic Technologies Limited (ASX:GTG)?

Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX

Genetic Technologies Limited, Annual General Meeting, Dec 10, 2020

Genetic Technologies Limited to Report Q4, 2020 Results on Oct 30, 2020

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Provides Update on COVID-19 Risk Test

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Receives Delisting Notification Letter from Nasdaq

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Regains Compliance with Nasdaq Stockholders Equity Requirement

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $5.125 million.

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance